DA Yardley

Phase II study of bevacizumab and everolimus (RAD001) in the treatment of advanced renal cell carcinoma (RCC)

Robert C. Whorf, John D. Hainsworth, David R. Spigel et al. · Journal of Clinical Oncology · 2008 · 73 citations

Urology, Angiogenesis, Genitourinary Cancer +12

Phase III trial of sunitinib (SU) in combination with capecitabine (C) versus C in previously treated advanced breast cancer (ABC).

John Crown, Véronique Dièras, DA Yardley et al. · Journal of Clinical Oncology · 2010 · 68 citations

Breast Oncology, Cancer Management, Immunotherapeutics +17

Abstract S1-04: A phase II study of adjuvant paclitaxel (T) and trastuzumab (H) (APT trial) for node-negative, HER2-positive breast cancer (BC)

SM Tolaney, WT Barry, CT Dang et al. · Cancer Research · 2013 · 36 citations

Dfs Events, Breast Oncology, Overall Survival +12

Clinical Benefit Rate and Time to Response in RIBBON-1, a Randomized, Double-Blind, Phase III Trial of Chemotherapy with or without Bevacizumab (B) for the First-Line Treatment of HER2-Negative Locally Recurrent or Metastatic Breast Cancer (MBC).

Nicholas J. Robert, Véronique Dièras, John A. Glaspy et al. · Cancer Research · 2009 · 35 citations

Breast Oncology, Cancer Management, Pharmacotherapy +16

Results of ENCORE 301, a randomized, phase II, double-blind, placebo-controlled study of exemestane with or without entinostat in postmenopausal women with locally recurrent or metastatic estrogen receptor-positive (ER+) breast cancer progressing on a nonsteroidal aromatase inhibitor (AI).

DA Yardley, Roohi Ismail‐Khan, Paula Klein · Journal of Clinical Oncology · 2011 · 24 citations

Breast Oncology, Cancer Management, Gynecology +20